Good day, and thank you for standing by. Welcome to CONMED’s Second Quarter Fiscal 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today’s conference is being recorded. Before the conference call begins, let me remind you that during the call, management will be making comments and statements regarding its financial outlook, its plans and objectives. These statements represent the forward-looking statements that involve risks and uncertainties as those terms are defined under the federal securities laws. Investors are cautioned that any such forward-looking statements are not guarantees of future events, performance or results. The company’s actual results may differ materially from its current expectations. Please refer to the risks and other uncertainties disclosed under the forward-looking information in today’s press release as well as the company’s SEC filings for more details on the risks and uncertainties that may cause actual results to differ materially. The company disclaims any obligation to update any forward-looking statements that may be discussed during this call, except as may be required by applicable law. You'll also hear management refer to non-GAAP or adjusted measurements during this discussion. While these figures are not a substitute for GAAP measurements, management uses these figures to aid in monitoring the company’s ongoing financial performance from quarter to quarter and year to year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the company, excluding credits or charges that are considered by the company to be special or outside of its normal ongoing operations. These adjusted items are specified in the reconciliation supporting the company’s earnings releases posted on the company’s website. With these required announcements completed, I will turn the call over to Curt Hartman, CONMED’s Chair of the Board, President and Chief Executive Officer, for opening remarks. Mr. Hartman?

Thank you, Amy. Good afternoon and thank you for joining us for CONMED’s second quarter 2024 earnings call. With me on the call is Todd Garner, Executive Vice President and Chief Financial Officer; and Pat Beyer, our Chief Operating Officer. Today, we will share with you our second quarter results and the overall outlook for our business. We will then open the call to your questions. I’ll start by reviewing our second quarter results. Total sales for the quarter were $332 million, representing a year-over-year increase of 4.5% as reported and 5.2% in constant currency. This performance delivered a record high quarterly sales result and was within our range of expectations. From an earnings perspective, during the second quarter, our GAAP net income totaled $30 million. This compares to net income of $13.7 million in the second quarter of 2023. Excluding special items that affected comparability, our adjusted net income of $30.6 million increased 17.2% year-over-year, and our adjusted diluted net earnings per share of $0.98 increased 18.1% year-over-year. Overall, we had several areas of strong financial performance in the quarter to include gross margin, adjusted EPS and our leverage ratio, which Todd will cover. Jumping into the key product categories, on the Orthopedic side of the business, we did not clear the supply constraints to the level we had expected. While the absolute dollar level of back order is back to normal, the current mix is far more weighted to our core single-use disposables in implant categories, and this by nature creates inefficiencies for our sales teams. Those missed opportunities resulted in lost sales as customers have alternatives in many of these categories. Further, this slows our team’s ability to be fully on offense going after new customers. This leaves us behind our initial plan entering Q3 and requires us to lower guidance for the remainder of the year. We understand this performance is frustrating for both our customers and our investors. On the general surgery side of the business, demand remained healthy across the portfolio. Regarding AirSeal, while it is still very early in the rollout of the new surgical robot, I wanted to provide you with some insight into what we are seeing after its first full quarter in the market. First, in the quarter, our U.S. AirSeal capital unit sales grew faster than they did in the prior year quarter. We are seeing no sales slowdown on AirSeal capital. Second, we understand that the first locations to receive the new robot were likely a targeted list of key customers. We also understand these locations are expected to commit to a certain number of procedures using the full feature set of the robot before they make any adjustments based on their preference. Against that backdrop in this very early window, our initial surveillance shows that the percentage of surgeons that returned to AirSeal after their initial committed number of procedures on the new robot appears to be consistent with the percentage of surgeons that chose AirSeal on the previous generation. This shows that clinical precision insufflation at low pressure remains a user preference. Third, AirSeal is used in roughly one-third of robotic surgical procedures today, and those surgeries are concentrated in the longer, more complex procedures such as prostatectomy, nephrectomy, hysterectomy, and bariatric surgery. These procedures typically stress standard insufflation due to leaks, smoke evacuation, suction requirements, and large cavity volume demand. We believe, and our early surveillance confirms that based on patient outcomes and numerous published clinical studies that the procedures most likely to use AirSeal today will be the same procedures that use AirSeal with the new robot. I will now turn the call over to Todd, who will provide a more detailed analysis of our Q2 financial performance and take you through our updated full year guidance.

Thank you, Curt. All sales growth numbers I reference today will be given in constant currency. The reconciliation to GAAP numbers is included in our press release. As usual, we have included an investor deck on our website that summarizes the results of the quarter and our updated guidance. For the second quarter of 2024, our total sales increased 5.2%. For Q2, our sales in the U.S. increased 6.1% versus the prior year quarter and our international sales grew 4.0%. Worldwide orthopedics declined 0.1% in the second quarter. In the U.S., orthopedic sales declined 0.4% and internationally orthopedic sales grew 0.1%. We’ve talked about our supply chain issues in our sports medicine and foot and ankle businesses, and we expected Q2 to be a transition back to offense. As Curt said, that transition is taking longer than we expected. Total worldwide general surgery revenue increased 9.4% in the quarter. U.S. general surgery revenue grew 8.9% while internationally general surgery revenue increased 10.5%. So the general surgery side of the business continues to be healthy and perform in line with historical trends. Consistent with the data that Curt provided on AirSeal, we continue to see very good global growth in that product line. Now let's move to the expense side of the income statement. We will discuss expenses and profitability in the second quarter, excluding special items, which include charges for acquisitions and contingent consideration, termination of distributor agreements, legal matters, software implementation costs, amortization of intangible assets and amortization of deferred financing fees net of tax. Adjusted gross margin for the second quarter was 55.3%, an increase of 90 basis points compared to the prior year quarter. Research and development expense for the second quarter was 4.2% of sales, 10 basis points lower than the prior year quarter. Second quarter adjusted SG&A expenses were 36.9% of sales, 50 basis points lower than the prior year quarter. On an adjusted basis, interest expense was $8.2 million in the second quarter. The adjusted effective tax rate in Q2 was 24.0%. Second quarter GAAP net income was $30.0 million. This compares to GAAP net income of $13.7 million in Q2 of 2023. GAAP earnings per diluted share were $0.96 this quarter compared to $0.43 a year ago. Excluding the impact of special items discussed earlier, in the second quarter, we reported adjusted net income of $30.6 million, an increase of 17.2% compared to the second quarter of 2023. Our Q2 adjusted diluted net earnings per share were $0.98, an increase of 18.1% compared to the prior year quarter. Turning to the balance sheet, our cash balance at the end of the quarter was $28.9 million compared to $33.9 million as of March 31. Accounts receivable days as of June 30 were 65, compared to 70 at the end of March and 65 a year ago. Inventory days at quarter end were 196, compared to 207 in March and 200 a year ago. Long-term debt at the end of the quarter was $965.2 million versus $990.1 million as of March 31. Our leverage ratio on June 30th was 3.8 times, which was better than we expected. So all balance sheet metrics moved in the right direction in the quarter and were improving in our working capital controls. Cash flow provided from operations in the quarter was $43.3 million, compared to $26.7 million in the second quarter of 2023. Capital expenditures in the second quarter were $3.6 million, compared to $4.5 million a year ago. Now let's turn to financial guidance. The revenue in the first half of the year is very close to what we expected at the beginning of the year. However, we expected to have better improvement in our global orthopedics business at this point. We knew we had supply challenges to work through early in the year, and we expected our teams to be fully back on offense by July 1st. While we have made significant improvements with the supply chain and our backorder is back to pre-pandemic levels, we remain hand to mouth on too many items, which is impeding our ability to be fully back on offense. Of course, this is a central focus for us, and we believe that we should be in a much stronger position by the end of the year. In Q1 we grew 5.9% and in Q2 we grew 5.2%, both against the strong growth rates we saw throughout 2023. So we've grown between 5% and 6% constant currency in the first half of the year. We think it's prudent to expect that same level of growth in the second half of the year, with Q3 on the lower part of that range. We project about 50 basis points of currency headwind in the third quarter and immaterial FX in Q4. That would put our full year reported revenue guidance between $1.305 billion and $1.315 billion. Our focus will be to strengthen our operational foundation over the next six months, increase the confidence of our sales forces, particularly in orthopedics, and to be back to full offense by the start of 2025. With orthopedics being slower in the back half of the year than we expected, that has an impact on gross margins. For the first six months of 2024, we improved gross margins by 130 basis points compared to 2023, consistent with our initial guidance for the year of improvement between 100 and 150 basis points, and we continue to project improving margins sequentially. We expect Q3 to be in the mid-56% range and Q4 to be around 57%. That would put us around 100 basis point improvement on the year with the mix engine still very positive and driving us northward. Again, our focus over the next six months will be to improve our internal operations, and we believe that will allow us to continue to improve margins at a higher pace than the vast majority of MedTech. We've included in our IR deck how this revised guidance impacts our original 2024 guidance for SG&A, interest expense, and the tax rate. We will continue to invest in the business to improve our revenue growth, but grow expenses slower than revenue. We project EPS growth to be between 9% and 11% in Q3 and between 13% and 18% in Q4. That would put our new full year guidance for adjusted EPS between $3.95 and $4.02, representing growth between 14.5% and 16.5%, still much better than the vast majority of MedTech. While we're disappointed by the need to reset our guidance lower than our initial expectations for the year, we believe these numbers are responsible and demonstrate a healthy growth company on the top and bottom lines with upside in the future. We are focused on executing and winning in the marketplace with our improving engine. And with that, we'd like to open the call to your questions and turn it back to Amy.

Thank you. Our first question comes from Rick Wise with Stifel. Your line is open.

Good afternoon to you both. First, I appreciate the good things about the quarter and the first half. It's frustrating to hear about the second half. But can you help us better understand exactly what's happening with the supply chain, what specifically has not ramped which specific products, and help us understand what you can do, what you are doing to get it back on track and what's taking so long, frankly?

Yes. Rick, a lot to unpack in that question. There's a number of things. Let me start with the products as we said in the script, key implantables in orthopedics, and that includes not only sports medicine, key markets of knee and shoulder, but also in the foot and ankle business. Now, I would say with that comment, foot and ankle exited the midpoint of the year in much better shape than the knee and shoulder implant categories. That's where we're still struggling to catch up. Part of the challenge is variability and surprises in our supplier base. As an example, we've had seven suppliers unexpectedly close their doors on us this year. And not just us, but everybody they were serving. And this is not a business where you can just rapidly pick up things and start producing tomorrow night after they close tonight. It takes time and validation and qualification, and it only takes one component to put a product on a supply constraint. And so those are the types of things we're dealing with. We've had other individualized issues, machine downtimes that crimp supply. We've had material availability issues. So it's not one thing I would point to that is slowing everything down. It's been a host of issues. And the teams in our manufacturing sites are very dedicated and focused and working diligently to find alternate suppliers, to qualify those alternate suppliers, to get product availability in stock to really focus on the key items that our sales teams and customers are asking for. And everybody's frustrated. I think we understand that clearly.

Right. And just to follow up, you gave some very detailed guidance, Todd, and just thinking, if I get the third quarter right, I'm going to get to the fourth quarter in the year. Just you're implying operating margins step up, I think, 70 basis points or so sequentially. But my rough initial math here, and maybe I'm just way off, you'll help me, is third quarter sales maybe in the $319 million, $320 million kind of area, and EPS at $0.99 based on just my rough back of the envelope hearing your comments. Does that sound like the place that you'd hope people would be?

Yes. I'm going to stick to my disclosure, Rick, if you don't mind. Low 5% growth constant currency with 50 basis points of FX headwind in Q3, and then we said 9% to 11% growth in EPS.

Thank you. And our next question comes from the line of Robbie Marcus with JPMorgan. Your line is open.

Okay. Thanks for taking the questions. Appreciate it. Two for me. First, Todd, when we came in, I remember we met at the J.P. Morgan conference in January this year, and at that point the elevated margin expansion targets for 2024 and 2025 were still on the table. You've clearly had supply issues this year. Are those margin targets gone at this point? Are they still feasible to get back to at some point in the future, or have there been more permanent shifts in the business that take away that type of expansion?

Great question, Robbie. Yes, we're definitely on the same track right, as far as improvements, but this is a speed bump that's going to delay us getting there. So back in the fall of 2022, we put a three-year kind of long-range plan out there that would get us around 60%. We said at the end of 2025. So now what I just said was we're going to be around 57% at the end of 2024. So in order to get to 60, I'd have to improve 300 basis points in that 12-month period, while that's not impossible, I don't think that's likely. So I think we're likely going to be short of what we said in the fall of 2022 for the end of 2025. But we still are enjoying about 100 basis points of tailwind from the mix. And so we still see that mix tailwind, and so it's just a matter of when we get there, and it's going to take a little longer than we thought a couple of years ago. But the margin improvement story I still think is one of the best in MedTech, and it does continue here.

Got it. Okay. Then, maybe just to follow up on Rick's question, last year was the warehouse software issue. This year has been supply issues. Before that, I believe there were a couple of years ago, it was a sales force expansion. At what point do you need to maybe broaden the controls at the company and review and overhaul some of the quality issues and processes in place here? For a company your size, I'm surprised there are so many disruptive issues that happen just wondering if you think about that and how we should think about any layered expenses moving forward to implement better quality controls? Thanks.

It's a good question, Robbie. And I think as you walk through those topics, in 2021, we did a sales force expansion because the markets were recovering from COVID, and as it turned out, there were two other iterations of COVID that kicked in after that sales force expansion. So it made it look as though our sales force expansion was mistimed. And I think nobody at that point in time could predict the variance of COVID and when they were going to or not hit. The warehouse issue was in the fourth quarter of 2022. That was an absolute execution issue on our part. Proud of the team, the way we remediated it, but nonetheless, it was a disruption, disruption to customers, disruption to our financial performance. And we have been dealing since the third quarter of last year with supply chain challenges from our supply base and from our internal issues. As companies scale, you do put more systems, more expense, more infrastructure in place, people, both people and systems around that and controls. I think we've been doing that appropriately as we look at areas that we believe need investment. I think we've been diligent with doing that. Certainly worse, frustrated by these hiccups and by these missteps as anybody is. Our teams are frustrated and we are frustrated, as I said in my script, customers and investors. And that's very, very challenging to deal with. And we are all committed to solving and remediating and getting these things behind us. Is there something systemic we need to do? We challenge ourselves every day with those questions, and I think we're doing the right things.

Thank you. And our next question comes from the line of Vik Chopra with Wells Fargo. Your line is open.

Hello, this is Dino Weinstock on for Vik Chopra. One question, I guess, further on the supply chain challenges. What kind of confidence do you have that this won't bleed into 2025? And do you have any expected timeline when you expect to fully recover? Thank you.

Yes. Good question. We're probably a little bit hesitant. We had thought at this point in the year we would have most of this behind us. And we’ve had some surprises that have popped up that were not on our radar screen. We have a very detailed plan as we look at the third quarter. As I noted earlier, we feel like we’re on the other side of things as it relates to our foot and ankle business back in solid supply there. It is really the implant categories in the shoulder and the knee where we’re kind of hand to mouth and struggling. We just cleared a key category with our arthroscopic enabling devices, getting back into full stock, getting our sales teams back on full offense there. The implant categories are the two remaining challenges, and we think as Todd talked about in his commentary, we thought the guide for the second half would be a little slower in Q3 and closer to the higher end in Q4. So that implies that we think we’ll be working through a lot of it in Q3 and be in better shape as we get into Q4. But we’re trying to give ourselves a little extra time given what we’ve gone through here in the first six months.

Got it. Thank you for the answer. Another question, I guess, on the F&A side, what trends are you seeing in the lower extremities market during Q2, and are you expecting second half growth to get back on track?

The trend question is relative to CONMED or the market in general?

The market.

I think we still believe the foot and ankle market is a great market, a growth market, and a market we want to be in, and a market that we have a great asset to participate. Obviously, we’ve struggled because of our supply chain challenges, and we think now that we have the majority of that behind us, that we should be getting back on offense here. Further, we’ve added, I think we noted on the last call that we have moved some of the sports medicine-related foot and ankle products into the foot and ankle business to further support that offering, as well as have done an initial rollout and launch of BioBrace, which brings along more implantations of lower extremity foot and ankle products that our portfolio has. So we think we’ve got the right offense and it’s just getting them back on. We think we’ve got the right portfolio, just getting them back on offense with product availability, which I think that is the one part of orthopedics that we do believe. We exited the mid-year point where we thought we would.

Thank you. And our next question comes from Travis Steed from BofA. Your line is open.

Hey, I kind of wanted to follow up on Robbie’s margin question, but I ask it on the revenue side. I think you’ve always talked about achieving kind of double-digit growth this year. It’s kind of 5% to 6%. Is this 5% to 6% and maybe a little bit better 6% to 7% kind of the right place to be longer term?

No, we still think we’re capable of much better than that, Travis. We still have that same 30% plus of our portfolio that should be very healthy double digits we think under normal circumstances should be there. So if that 30%, that ought to be able to deliver close to 6% growth just on its own. And so the rest of the 70% was mid-single digits, then you’re in those high single digits just with kind of that being normal. So we don’t think this is normal. And our expectations are certainly to be a faster grower than this. But 5% to 6% growth while disappointing to us, I think, is still probably above average in MedTech. And certainly our EPS growth is above average for MedTech. So even at these disappointing levels, it is a healthy, growing, profitable business, but not growing as fast and not as profitable as we expected at the beginning of the year, granted.

Great. Thank you. And another question. And just like when you think about the rest of the markets, I know you had your supply issues. But I don’t know if you think about the market that there’s been any kind of change in the market just because like you’re not the only company that’s kind of resetting the second half year and having more kind of inaccuracy. And so I don’t know if there was just some sort of moderation in ortho markets or kind of anything you’ve seen on the margin.

Travis, I don’t think there’s anything we would point to. I think we believe commercially, our teams, and we just did a big round of international meetings. The only thing we would point to in the markets are the strikes in Korea are continuing longer than anybody had anticipated, and events in China have slowed the overall China market. But those are smaller markets for CONMED. They’re growth markets for CONMED, but they’re smaller. But the majority of our big markets, Canada, the U.S., and Western Europe, we see pretty healthy underlying markets. Pat, I don’t know if you want to add anything to that; you’ve spent a lot of time.

Curt, I would just agree with what you're saying, and would again, call out Japan market also continuing to grow well from the market standpoint.

Thank you. And our next question comes from the line of Mike Matson with Needham. Your line is open.

Yes. Thanks for taking my questions. I just want to ask a couple on general surgery. So the growth was obviously good, much better than orthopedics. But it’s probably a little slower than I would have expected, just given that’s where a couple of your bigger growth drivers are. So what are your thoughts on that business? Is there anything going on there? I understand the supply chain is more on the ortho side, but…

Yes, I mean, I think that business is pretty close to historical rates there, Mike. AirSeal is definitely good. Smoke is a little soft. We had a transitory quality issue that we dealt with and has been remediated. It did affect us a little bit in Q2. So Smoke was soft. But we think that’s temporary. And other than that, I think things were pretty normal on general surgery.

Okay. And then just looking into the second half, I would assume that the growth, you expect similar growth overall for the company. So the two businesses, general surgery and orthopedics, I would assume would be kind of similar to what we saw in the first half as well.

Yes, yes. Our guidance kind of assumes that orthopedics stays challenged a little bit for longer than we thought originally, of course. And so – but the general surgery business, we think will continue to do what it’s been doing.

Thank you. Our final question comes from the line of Kristen Stewart with CL King. Your line is open.

Hi. Thanks for taking the question. I was just wondering if there’s any risk that we could see some of these supply constraints and supply issues bubbling over into the general surgery business? Or do you still have confidence in that for the balance of the year being unaffected?

No. Right now, Kristen, we feel very good about the general surgery side of the business, the product availability, the manufacturing controls. Obviously with a product line like AirSeal, a product line like Smoke, we very early brought those under our complete manufacturing control and have a lot of redundancy for products like that. Some of the orthopedic categories have multiple generations of products and we don’t control all of those. That is part of our cleanup is to really focus our energy efforts on the key product lines and start transitioning more customers. So we are not anticipating that. And trust us, we are watching those categories very closely. Thank you, Amy. And just wrap up here today and say thank you, everybody, for your time. We look forward to speaking with you on our next earnings call.

And this concludes today’s conference call. Thank you for participating. You may now disconnect.